J B Chemicals & Pharmaceuticals, a Rs.1,000 crore plus pharma major from Mumbai, has posted net profit growth of 7.8 per cent during the first quarter ended June 2015 to Rs.34.28 crore from Rs.31.79 crore in the corresponding period of last year. Its EBDITA improved by 10.9 per cent to Rs.55.02 crore from Rs.49.60 crore. Its net sales improved by 8.7 per cent to Rs.279.15 crore from Rs.256.71 core. EPS worked out to Rs.4.04 as against Rs.3.75 in the last period.

The domestic formulations business went up by 11.4 per cent to Rs.114.45 crore. The focus products group continued to do well with growth of 19 per cent. The contrast media products sales in domestic market improved by 13.5 per cent to Rs.9.75 crore. The company continues focus on cardiovascular products and topical preparations to drive the growth for the division during the year.

Its exports of formulations improved by 7.1 per cent to Rs.128 crore. Its export of formulations to RoW markets improved by 9.2 per cent to Rs.92.22 crore. It is making investments for the growth of this business particularly growth in the US market. Recently, the US FDA approved ANDA for Lithium carbonate extended-release tablets USP 300mg. The company plans to commercialize this product in Q4 of this year. However, exports to Russia-CIS market declined to Rs.11.34 crore and API business improved slightly to Rs.23.99 crore.